Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ...

Additionally, data presented at the 2023 European Society for Medical Oncology (ESMO) Congress revealed that the combination of cadonilimab and lenvatinib as first-line treatment for advanced HCC ...

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a trial last year, the firm’s cancer drug outperformed the world’s best ...

An announcement from Akeso, Inc. ( (HK:9926) ) is now available. Akeso, Inc. has announced that its board of directors will meet on August 26, 2025, to consider and approve the interim results for ...

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological ...

Akeso's partner, Summit will initiate HARMONi-7, a phase III trial in 1L PD-L1 high advanced NSCLC, in early 2025. HONGKONG and CALIFORNIA, Sept. 8, 2024 /PRNewswire/ -- Akeso (9926.

Akeso, Inc. (HK:9926) has released an update.Akeso, Inc. has successfully completed a placement of 31.7 million new shares, raising approximately HK$1.924 billion. The shares were placed with ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF ...

Akeso’s bispecific antibody improved overall survival in first-line patients with severe gastric cancer or gastroesophageal junction adenocarcinoma in a phase 3 trial, acing the primary endpoint.

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet Provided by PR Newswire Mar 7, 2025, 5:03:00 AM ...

Akeso’s new drug, which is not a generic, has been approved by China’s pharmaceutical regulator for some lung cancer patients. But it is still years away from being sold in the US.